Screening Blood Samples for Cancer-Driving Mutations More Comprehensive Than Analyzing Traditional Tumor Biopsy, Dana-Farber Cancer Institute and Harvard Medical School Study

Published: Apr 08, 2013

Researchers using a tool called BEAMing technology, which can detect cancer-driving gene mutations in patients' blood samples, were able to identify oncogenic mutations associated with distinct responses to therapies used to treat patients with gastrointestinal stromal tumors (GIST), according to a researcher who presented the data at the AACR Annual Meeting 2013, held in Washington D.C., April 6-10.

Back to news